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Abstract: This study compared the cumulative live birth rates following Intracytoplasmic sperm
injection (ICSI) versus conventional in vitro fertilization (cIVF) in women aged 40 years or more
and unexplained infertility. A cohort of 685 women undergoing either autologous conventional
IVF or ICSI was retrospectively analyzed. The effects of conventional IVF or ICSI procedure on
cumulative pregnancy and live birth rates were evaluated in univariate and in multivariable analysis.
In order to reduce potential differences between women undergoing either IVF or ICSI and to obtain
unbiased estimation of the treatment effect, propensity score was estimated. ICSI was performed in
307 couples (ICSI group), whereas cIVF was performed in 297 couples (cIVF group), resulting in 45
and 43 live deliveries, respectively. No differences were observed in morphological embryo quality,
in the number of cleavage stage embryos, in the number of transferred embryos, and in the number
of vitrified embryos. As for the clinical outcome, no differences were observed in pregnancy rate,
cumulative pregnancy rate, live birth rate, cumulative live birth rate, and abortion rate. The present
results suggest that ICSI is not associated with increased likelihood of a live birth for unexplained,
non-male factor infertility, in women aged 40 years or more.
Keywords: in vitro fertilization; ICSI; IVF; non-male factor infertility; cumulative live birth rates
1. Introduction
Intracytoplasmic sperm injection (ICSI) was introduced in 1992 in order to treat infertility in
couples with severe male factor [1]. Since then, the use of ICSI as an alternative to conventional in vitro
fertilization (cIVF) has increased steadily, with a proportion rising worldwide from 47.6% of all IVF
cycles in 2000 to 66% in 2010, and exceeding 90% in some countries [2,3]. In Italy, the use of ICSI was 6
times more frequent than that of cIVF in 2014 [4].
Interestingly enough, the largest increase in ICSI application has been observed among couples
without male factor infertility (from 15% in 1996 to 67% in 2012) [5]. Indeed, ICSI has been suggested
as the elective treatment for couples with unexplained infertility [6]. Furthermore, ICSI has been
used more and more as a general routine for IVF, due to the belief that it could prevent up to 30% of
fertilization failures [7]. However, so far there is no clear evidence that ICSI leads to better reproductive
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outcomes in non-male infertility, compared to cIVF. A previous Cochrane review of cIVF versus ICSI in
couples with infertility not related to a male factor did not report differences in pregnancy rates (PR).
However, the review did not include in the analysis randomized data with live birth rates (LBR) [8].
More recent data seem to confirm that cIVF and ICSI result in similar reproductive outcomes in both
non-male infertility [9] and patients with a poor response to ovarian stimulation and few oocytes
retrieved [10,11].
In spite of these results, ICSI has been suggested in alternative to cIVF for women with age-related
infertility, whose proportion is dramatically increased over the last decades [12]. As a matter of fact,
oocytes retrieved from older women are often of lower quality [13], and cIVF could hypothetically
result in decreased fertilization rates in these patients, due to problems in sperm-oocyte interaction [14].
Therefore, for many clinicians, ICSI should be the preferred method in this population, but such a
choice is not based on solid grounds, as clinical evidence is currently lacking.
The purpose of the present study was to compare ICSI and cIVF in women aged 40 years or more,
affected by unexplained infertility. The primary end-point was the cumulative live birth rate, including
transfers of both fresh and frozen embryos. Secondary end points were fertilization rate, embryo
morphological score, implantation rate, abortion rate.
2. Materials and Methods
2.1. Patient Population
In this retrospective analysis we included a cohort of women aged ≥ 40 years, with unexplained
infertility, undergoing either cIVF or ICSI in the years 2012–2018, at a single academic IVF unit. Only
autologous cycles were considered. All women included in the study had ovulatory cycles and at least
patency of one fallopian tube at sonosalpingography (SSG), whereas all male partners had normal basic
semen parameters according to the indications of WHO 2010. Exclusion criteria were: Any known
cause of female infertility (i.e. previous history of pelvic inflammatory disease, positive anti-Chlamydia
IgG, endometriosis, anovulation, etc), female body mass index (BMI: Kg/m2) > 32 kg/m2, early follicular
phase follicle stimulating hormone (FSH) > 20 UI/l and/or anti-Mullerian hormone (AMH) < 0.1,
cycles with pre-implantation genetic diagnosis, and combined insemination (cIVF/ICSI) of sibling
oocytes. The study was performed in accordance with the Helsinki Declaration and with approval of
the Institutional Review Board. Since this was a retrospective analysis of data routinely collected from
treatments and patients, a specific informed consensus was not required, according to the rules of the
Department of Ob&Gyn of S. Anna hospital.
2.2. ART Procedure
Controlled ovarian stimulation (COS) was performed either with recombinant FSH (rFSH), human
Menopausal Gonadotropin (HP-hMG) or rFSH plus recombinant luteinizing hormone (rLH), under
pituitary suppression. The choice of the starting gonadotropin dose was based on age, BMI, antral
follicular count (AFC), AMH concentrations, as well as on the response to previous COS. In the absence
of any pre-fixed criteria, the COS regimen (type of protocol and type of medication) was decided and
prescribed by different physicians of the IVF unit, according to their own clinical experience, as per
real-life clinical practice.
Both long and short protocols were used. The long protocol was performed administering
buserelin (Suprefact®, Hoechst, Frankfurt, Germany; 900 mcg/d intranasally) starting from the late
luteal phase of the previous cycle. After approximately two weeks, pituitary suppression was verified
(appearance of a menstrual bleeding, serum estradiol < 50 pg/mL, endometrial thickness <3 mm)
before starting COS.
In the short protocol, either the GnRH-antagonist cetrorelix (Cetrotide®, Merck, Darmstadt,
Germany) or ganirelix (Orgalutran®, Merck Sharp & Dome, Kenilworth, NJ, USA) were started at a
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subcutaneous dose of 0.25 mg/d according to a flexible schedule, when at least one follicle ≥ 12 mm in
mean diameter was observed at ultrasound (US).
COS was monitored by serial transvaginal US and serum estradiol (E2) measurements performed
every second day from stimulation day 6–7. COS continued until at least two follicles reached 18
mm in mean diameter, when ovulation was triggered by injecting either 10,000 international units
(IU) of hCG (Gonasi HP®, IBSA, Lugano, Switzerland) or 250 mcg of rHCG (Ovitrelle®, Merck,
Darmstadt, Germany) subcutaneously. US-guided transvaginal oocyte aspiration (OPU) was performed
approximately 36–37 h after hCG administration, under local anesthesia (paracervical block). Oocytes
were immediately recovered from the follicular fluid, then washed in buffered medium and stored
until fertilization procedure.
2.3. Preparation of Semen Samples and in Vitro Fertilization
Semen samples were examined to assess sperm concentration, motility, and morphology according
to the World Health Organization guidelines [15]. Samples were then prepared by density gradient
centrifugation in order to select motile, morphologically normal spermatozoa.
The embryologist on duty the day of OPU decided the insemination method in agreement with the
physician in charge of the treatment. According to all physicians working in the unit, the decision was
oriented mainly by two parameters: previous attempts and duration of infertility. However, criteria
varied among doctors, whereas they were not applied in all cases uniformly. Given the lack of shared
clinical guidelines, such an approach to treatment in this particular group of patients is reported as
rather common [16].
Conventional IVF or ICSI were performed on all available oocytes within 4 hours after oocytes
collection and, after 16–18 hours of incubation in controlled atmosphere, the occurrence of normal
fertilization was assessed.
2.4. Embryo Selection and Transfer
In total, 1787 embryos were obtained in 685 IVF cycles. Zygotes were placed in pools in 4-wells
dish (Thermo Scientific, Roskilde, Denmark) and embryos were cultured in pre-equilibrated Cleavage
medium (Cook) overlain with mineral oil using incubators (Minc, COOK, Bloomington, IN, USA) in a
gas phase consisting of 5% O2, 6–7% CO2, balanced with N2.
All cleaved embryos were morphologically evaluated under a conventional stereomicroscope,
using the IMCS score by Holte [17]. A total number of 900 embryos were selected on day 2 or 3 for
transfer in uterus (1.3 ± 0.8 per patient), which was performed using a soft catheter, under ultrasound
guidance. According to the policy of our IVF unit during the time period under study, one or two
embryos were transferred on day 2/3 post-fertilization. The remaining embryos (if any) were kept in
culture until the blastocyst stage. Only embryos reaching the blastocyst stage could be vitrified. The
luteal phase was supported by administering 180 mg/day natural progesterone (Crinone 8®, Merck,
Darmstadt, Germany) for 15 days.
Pregnancy was assessed by serum hCG assay after 15 days from embryo transfer (ET) and then
confirmed if at least one gestational sac was visualized on transvaginal US after two further weeks.
Only cases with US confirmation of pregnancy were counted in the calculation of pregnancy rate,
whereas biochemical pregnancies were not considered.
2.5. Statistical Analysis
Continuous data are presented as mean and standard deviation (SD), while categorical data are
presented as rate and proportion.
The effects of cIVF or ICSI procedure on pregnancy and live birth rates were evaluated in
univariate and in multivariable analysis. In univariate analysis, comparisons of continuous data were
performed using either the unpaired Student’s t-test or Wilcoxon Mann-Whitney test, according to data
distribution; comparisons of categorical data were performed using either Chi-square test or Fisher’s
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exact test, as appropriate. In multivariable analysis outcomes were evaluated using two different
approach: conventional multivariable analysis and analysis using Propensity Score.
2.6. Propensity Score
In 1983, Rosenbaum and Rubin introduced the Propensity Score (PS) as a means to control for
confounding in observational studies [18]. The PS combines the information from all measured
confounders into one score and can be seen as a one-dimensional variable that summarizes the
multidimensional pretreatment covariates. Conditional on the PS, the treatment and the control groups
are expected to have the same distribution of measured confounders and therefore allows for a direct
comparison between groups [19].
In order to reduce potential differences between women undergoing either cIVF or ICSI and to
obtain unbiased estimation of the treatment effect, PS was estimated. In this study PS is the probability of
receiving IVF procedure conditionally on a priori selected variables. A multivariable logistic regression
model was performed with presence of cIVF or ICSI procedure as the dependent variable. Variables
included in the propensity score model were years of infertility, previous ART treatments, female
age, smoke, AFC, AMH, FSH, BMI, endometrial thickness, partner’s age, sperm concentration, sperm
progressive motility, proportion of spermatozoa with normal morphology, embryo morphological
score and number of embryos transferred.
All outcomes (pregnancy rate, cumulative pregnancy rate, live birth rate, cumulative live birth
rate) have been evaluated with conventional covariate adjustment and with PS adjustment; in both
approach results were reported as odds ratios (OR) with a 95% confidence intervals (95% CI).
All statistical tests were two-sided and p values of 0.05 or less were considered statistically
significant. All analysis was conducted using the SAS version 9.4 (SAS Institute, Cary, NC, USA)
software package.
3. Results
Among the 685 couples who met the inclusion criteria, 81 women did not obtain any mature
oocyte at OPU and were excluded from further analysis. The number of couples who failed to recover
any oocyte at ovum pick-up did not differ between cIVF and ICSI groups.
At least one mature oocyte was retrieved in the remaining 604 couples. Baseline characteristics of
the women included in the analysis are presented in Table 1.
Table 1. Basal characteristics of the patients in the two study groups.
cIVF (n = 297) ICSI (n = 307) p
Woman age (years) 41.1 ± 0.8 41 ± 0.8 0.9957
Years of infertility 2.8 ± 2.3 3.2 ± 2.4 0.0137
Couples with previous ART treatments (%) 80 (27%) 138 (45%) < 0.0001
BMI (Kg/m2) 22.6 ± 3.3 23 ± 3.9 0.3832
AFC 9.5 ± 5.7 10.3 ± 6.1 0.0697
AMH (ng/mL) 1.6 ± 2.1 1.4 ± 1.3 0.5644
Women who smoke 33 (11.1%) 44 (14.3) 0.2354
Partner’s age (years) 41.9 ± 5.2 42.8 ± 5 0.0770
Sperm concentration (Mln/mL) 80.2 ± 34.1 80.4 ± 38.9 0.3121
Progressive motility (A+B; %) 40.5 ± 4.8 40.3 ± 4.4 0.4126
Normal morphology (%) 5.0 ± 0.8 4.9 ± 0.8 0.3036
BMI, body mass index; AFC, antral follicular count; AMH, anti-Mullerian hormone; cIVF, conventional in vitro
fertilization; ICSI, Intracytoplasmic sperm injection.
ICSI was performed for 307 couples (ICSI group), whereas cIVF was performed for 297 couples
(cIVF group). All variables were similar between the cIVF and ICSI groups except for the years of
infertility and a history of previous ART treatments, which were both higher in the ICSI group. In total,
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388 patients (n = 217 in cIVF group, n = 169 in ICSI group) had never undergone an IVF treatment
before. Also, in this sub-group of patients, basal characteristics were similar except for the years of
infertility (see Table S1). Variables related to cycle outcome are shown in Table 2.
Table 2. Cycle outcome in the two study groups (univariate analysis).
cIVF (n = 297) ICSI (n = 307) P
Total FSH dose (IU) 2725 ± 1172 2816 ± 1287 0.3181
Mean FSH dose (IU) 265 ± 83 267 ± 87 0.9545
Total LH dose (IU) 1470 ± 767 1587± 892 0.5842
Mean LH dose (IU) 188 ± 89 184 ± 61 0.7537
Endometrial thickness (mm) 10.1 ± 2.4 9.9 ± 2.1 0.4445
Retrieved oocytes 5.8 ± 4.2 6.3 ± 4.6 0.2816
Mature (MII) oocytes 4.9 ± 3.4 4.9 ± 3.6 0.7006
MII/retrieved oocytes (%) 87.1 80,7 < 0.001
Fertilized oocytes 3.5 ± 2.8 3.2 ± 2.6 0.1701
Fertilization rate (%) 60,7 ± 28,3 52,1 ± 28,1 < 0.01
No fertilization (%) 6,7 (20/297) 9.4 (29/307) 0,2222
Cleaved embryos 3 ± 2.7 2.9 ± 2.5 0.8834
Transferred embryos 1.5 ± 0.7 1.4 ± 0.8 0.0899
Frozen embryos 0.4 ± 1 0.4 ± 1 0.6184
Mean embryo score 7.9 ± 1.8 7.9 ± 1.8 0.4458
PR/ET n.(%) 64 (10.4%) 63 (10.6%) 0.7567
Cumulative PR/OPU n. (%) 73 (12%) 72 (11.9%) 0.7459
LBR/ET n.(%) 38 (6.3%) 40 (6.6%) 0.9315
Cumulative LBR/OPU n.(%) 45 (7.5%) 43 (7.1%) 0.6901
Abortion rate n.(%) 28 (38.3%) 29 (40.3%) 0.7
FSH, follicle stimulating hormone; OPU, oocytes pick up; IU, international units; LH, luteinizing hormone; PR,
pregnancy rate; ET, embryo transfer; LBR, live birth rate
No differences were registered in the dose of exogenous FSH and LH, or in the thickness of the
endometrium at the end of COS.
The number of retrieved oocytes and the absolute number of mature (MII) oocytes did not differ
between the groups; however, the proportion of MII oocytes was higher in the IVF group, so was the
overall fertilization rate. When only MII oocytes were considered, the fertilization rate did not differ
between the study groups.
No differences were observed in morphological embryo quality, in the number of cleavage stage
embryos, in the number of transferred embryos, and in the number of vitrified embryos. As for the
clinical outcome, no differences were observed in pregnancy rate, cumulative pregnancy rate, live birth
rate, cumulative live birth rate, and abortion rate. As shown in Table 3, the results did not change even
after adjusting for several confounding variables and applying the Propensity Score.
In order to account for the potential confounding factor deriving from the number of previous
treatments, a sub-analysis including only patients at their first treatment was carried out. The results
are comparable to those from the general population examined and, even after correction with the
propensity score, it was not possible to demonstrate the superiority of one technique over the other in
terms of cumulative pregnancy rates and cumulative live birth rates (see Tables 4 and 5).
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Table 3. Cycle outcome in the two study groups (univariate analysis, multivariate analysis and analysis
after data correction and application of the PSM Propensity Score).
Univariate
OR (CI 95%)
Multivariate *
OR (CI 95%)
Adj with PS **
OR (CI 95%)
PREGNANCY, fresh ET (cIVF vs. ICSI) 1.064 (0.719–1.574) 1.018 (0.656–1.582) 1.035 (0.674–1.588)
PREGNANCY, fresh+frozen ET (cIVF vs. ICSI) 1.064 (0.732–1.545) 1.049 (0.693–1.588) 1.040 (0.695–1.555)
LIVE BIRTH, fresh ET (cIVF vs. ICSI) 0.979 (0.609–1.576) 0.881 (0.513–1.514) 0.924 (0.552–1.546)
Single pregnancy (n = 116) 0.729 (0.345–1.537) 0.399 (0.143–1.113) 0.692 (0.291–1.644)
Twin pregnancy (n = 11) 3.500 (0.145-84.694) == ==
LIVE BIRTH, fresh+frozen ET (cIVF vs. ICSI) 1.096 (0.698–1.723) 0.983 (0.592–1.633) 1.008 (0.619–1.642)
Single pregnancy (n = 125) 0.913 (0.430–1.942) 0.457 (0.162–1.289) 0.815 (0.339–1.962)
Twin pregnancy (n = 23) 3.500 (0.145–84.694) == ==
* Adjusted for years of infertility, previous ART treatments, female age, smoke, AFC, AMH, FSH, BMI, endometrial
thickness, partner’s age, sperm concentration, progressive motility, normal morphology, embryo morphological
score and number of embryos transferred ** Adjusted for Propensity score; CI, confidence intervals; OR, odd ratio.
Table 4. Cycle outcome in patients with no previous treatments in the two study groups
(univariate analysis).
cIVF
(n = 217)
ICSI
(n = 169) p
Total FSH dose (IU) 2745 ± 1153 2732 ± 1313 0.8456
Mean FSH dose (IU) 262 ± 80 260 ± 88 0.7328
Total LH dose (IU) 1531 ± 797 1578 ± 943 0.9699
Mean LH dose (IU) 191 ± 96 191 ± 63 0.5010
Endometrial thickness (mm) 10.2 ± 2.5 9.9 ± 2.2 0.2969
Retrieved oocytes 5.9 ± 4.0 6.7 ± 4.9 0.3253
Mature (MII) oocytes 4.8 ± 3.1 5.2 ± 3.9 0.9638
MII/retrieved oocytes (%) 85.9 ± 19.1 79.9 ± 19.6 0.0006
Fertilized oocytes 3.5 ± 2.6 3.4 ± 2.9 0.3204
Fertilization rate (%) 59.2 ± 28.9 51.8 ± 28.9 0.0102
No fertilization (%) 6.9 (15/217) 11.2 (19/169) 0.1364
Cleaved embryos 3.0 ± 2.5 3.1 ± 2.8 0.8418
Transferred embryos 1.5 ± 0.7 1.4 ± 0.8 0.1070
Frozen embryos 0.4 ± 1.1 0.6 ± 1.3 0.0691
Mean embryo score 8.0 ± 1.8 7.7 ± 1.8 0.1284
PR/ET, n (%) 45 (20.7%) 31 (18.3%) 0.5573
Cumulative PR/OPU, n (%) 53 (24.4%) 39 (23.1%) 0.7580
LBR/ET, n (%) 26 (11.9%) 19 (11.2%) 0.8224
Cumulative LBR/OPU, n (%) 32 (14.8%) 22 (13.0%) 0.6271
Abortion rate, n (%) 21 (9.7%) 17 (10.1%) 0.9006
Table 5. Cycle outcome in patients with no previous treatments in the two study groups (univariate
analysis, multivariate analysis and analysis after data correction and application of the PSM
Propensity Score).
Univariate
OR (CI 95%)
Multivariate *
OR (CI 95%)
Adj with PS **
OR (CI 95%)
PREGNANCY, fresh ET (cIVF vs. ICSI) 1.165 (0.700–1.938) 0.906 (0.515–1.594) 1.033 (0.604–1.768)
PREGNANCY, fresh+frozen ET (cIVF vs. ICSI) 1.077 (0.671–1.729) 1.049 (0.693–1.588) 0.945 (0.561–1.593)
LIVE BIRTH, fresh ET (cIVF vs. ICSI) 0.979 (0.609–1.576) 0.881 (0.513–1.514) 0.924 (0.552–1.546)
Single pregnancy (n = 116) 0.729 (0.345–1.537) 0.399 (0.143–1.113) 0.692 (0.291–1.644)
Twin pregnancy (n = 11) 3.500 (0.145–84.694) == ==
LIVE BIRTH, fresh+frozen ET (cIVF vs. ICSI) 1.156 (0.644–2.073) 0.895 (0.472–1.696) 0.697 (0.526–1.777)
Single pregnancy (n = 125) 1.019 (0.380–2.730) 0.742 (0.140–3.942) 0.800 (0.251–2.555)
Twin pregnancy (n = 23) 1.500 (0.055–40.633) == ==
* Adjusted for years of infertility, previous ART treatments, female age, smoke, AFC, AMH, FSH, BMI, endometrial
thickness, partner’s age, sperm concentration, progressive motility, normal morphology, embryo morphological
score and number of embryos transferred ** Adjusted for Propensity score.
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4. Discussion
Notwithstanding the lack of evidence-based guidelines, the routine use of ICSI has been proposed
for women in advanced reproductive age regardless the cause of infertility, with the rationale that ICSI
would be associated with a reduced likelihood of fertilization failure [20,21]. A higher fertilization rate
would result in an increased number of available embryos, a crucial issue especially in patients with a
low ovarian reserve and low oocyte yield, which is often the case in older women.
The issue is not of minor relevance. Indeed the number of women of advanced reproductive age
is constantly increasing worldwide: according to the last ESHRE report, in 2014 approximately 17% of
cIVF cycles and 20% of ICSI cycles were performed in women aged 40 years or older [4], whereas more
than 35% of women attending fertility clinics in Italy in 2016 were 40 years or older [22]. Data from US
report a similar picture, as in 2015, 16% of ART cycles were carried out among women aged 41–44
years [23].
Oocytes of older women were theorized to have structural defects that might reduce the fertilization
potential; one of the putative mechanisms suggested for a decreased fertilization rate in older women
would be the zona pellucida hardening. However, limited data from women at the extreme of
reproductive age range (45 years or more) with a normal partner did not confirm this hypothesis [24].
Recently, the results of a systematic review and meta-analysis of couples with well-defined
unexplained infertility suggested the use of ICSI instead of cIVF, regardless of female age, in order to
increase the fertilization rate per retrieved oocyte [6]. That meta-analysis included 11 studies, which
reported data on sibling oocytes randomly split to be inseminated either with ICSI or cIVF. However,
only four of the included studies reported pregnancy outcomes by insemination method. Furthermore,
as the authors pointed out, the studies used different criteria for selecting embryos for transfer, and the
patient groups were small and not comparable among different studies. Even more important, the
studies selected for the meta-analysis included patients with an average number of retrieved oocytes
between 10.8 and 16.3: this would suggest that the included women represented a subgroup of patients
with good prognosis.
At variance with those results, more recent data on patients of various ages reported comparable
or even higher fertilization rates per retrieved oocyte for cIVF than ICSI [9,10,16,25]. The largest
population-based cohort study published so far, which included women distributed on a wide age
range belonging to couples with non-male factor infertility, resulted in a similar cumulative live birth
rate (up to 6 treatment cycles) between cIVF and ICSI [9]. However, the results were not stratified
according to the woman age range. Another recent study in women aged between 40–43 years treated
for non-male factor infertility found that cIVF resulted in a higher fertilization rate per retrieved oocyte
compared with ICSI (57% versus 52%). This result, however, was partially explained by the larger
number of mature oocytes (MII) in the IVF group [16].
In this panorama, the present study is the first one investigating the cumulative live birth rate in
women aged 40 years or more with unexplained infertility, following either cIVF or ICSI. Our results
show that in this specific group of patients, cIVF and ICSI result in similar cumulative live birth rates
once all viable embryos are transferred. The insemination technique in our study, in fact, did not affect
embryo quality according to the morphological score [17], nor it affected the cumulative pregnancy
rate, the cumulative live birth rate and the abortion rate. Whereas the results related to these clinical
variables should be interpreted with caution, due to the limited number of observations, they are in
line with recent data from other groups [9,16], corroborating the notion that this particular subgroup
of patients would not benefit from ICSI, in the absence of a male-factor.
In our study, a higher proportion (but not the absolute number) of MII oocytes, together with a
higher fertilization rate per retrieved oocyte, were observed in cIVF group. This finding cannot be
explained by differences in pre-treatment clinical parameters, nor in the COS protocols, since all the
considered variables were comparable between the groups. An alternative explanation could be that
immature oocytes elected for cIVF could have completed nuclear maturation in vitro, since in cIVF
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the cumulus cells are left intact, whereas in ICSI, when oocyte denudation procedure was applied,
immature oocytes were immediately discharged.
When only mature oocytes were considered, fertilization rates tended to be higher in the IVF group
(p 0.07): this trend could not be explained by sperm quality, as the conventional semen parameters
were similar in the two groups. A potential explanation could be the oocyte damage caused by the
invasive procedure of microinjection [16,26,27], a mechanical injury somehow facilitated by advanced
maternal age. Should this hypothesis be confirmed in larger studies, ICSI could even turn out to be
contraindicated for older women in the absence of a male factor.
In the cited study by Tannus and coworkers [16], more zygotes and more embryos to freeze were
obtained in the cIVF group. Again, this probably depended on the larger number of MII oocytes in the
cIVF group. Unfortunately, it is not possible to know whether the higher number of frozen embryos in
the cIVF group would have resulted in higher cumulative pregnancy and live birth rates, since the
study did not included thawing cycles [16].
A very recent retrospective cohort study from Israel in couples with non-male factor infertility [28]
included women aged 35–45 years. By design, sibling oocytes were randomly assigned to either cIVF or
ICSI. The fertilization rate and the top-quality embryo rate were significantly higher for the oocytes in
the ICSI group (implantation rate and clinical pregnancy rate according to the method of insemination
were not end-points). However, when analyzing the subgroup of patients aged 40–45 years (a similar
age range to the patients enrolled in our study), differences were no longer significant, suggesting that
the putative advantage of ICSI over cIVF would be limited to younger patients.
However, even this hypothesis would be questionable according to the results of a similar recent
retrospective study on a large group of women with mean age 37, and normo-spermic partners [29]. In
that study, which had a design similar to ours, the fertilization rate, the number of frozen embryos,
the cumulative pregnancy rate and the live birth rate were significantly lower for the couples treated
with ICSI. In order to explain their findings, the authors suggested on one side a potential role of
natural selection of the sperm in cIVF, on the other side a detrimental role of ICSI as a consequence of
mechanical damage to both the oocyte and the sperm.
A limitation of the present study is represented by its retrospective design. Furthermore, the
choice between IVF and ICSI was somehow arbitrary, being based on both the number of previous ART
treatments and the years of infertility. Evaluation of outcomes in previous treatments is a fundamental
step to optimize the probability of success of an IVF treatment. However, couples do not always rely
on the same center after one or more failures, and the information relating to previous treatments may
not always be complete and exhaustive. The insemination method is therefore chosen without full
awareness of the previous results, in terms of fertilization rates and embryo quality. Whereas this
could represent a bias when analyzing the results in terms of pregnancies, a sub-analysis limited to
only women with no previous treatments (n = 217 in cIVF group, n = 169 in ICSI group) confirmed the
results obtained in the whole population (Tables 4 and 5).
Strengths of the study are represented by the number of subjects included and the use of the
PSM propensity score as a proxy variable that aggregates multiple confounding factors into a single
dimension. Indeed, PSM allows to mimic randomized controlled trials [30]. Several authors suggest
that it actually outperforms standard multivariable methods [31]. However, limitations in PSM were
highlighted in previous papers [32] and since we believe that neither method was better in this context,
we used both in our study. Furthermore, at variance with previous studies, basal semen parameters,
according to the latest WHO manual, were similar between the IVF and ICSI study groups. Whereas it
can be argued that basic semen analysis might have limited predictive value for pregnancy in couples
trying to achieve natural conception and in couples undergoing assisted reproductive technologies
(ARTs) [33], and several sperm functionality tests have been proposed [34], those have not yet been
included in the WHO manual for the definition of normal semen.
Against this background, the safety of cIVF and ICSI should also be discussed. In a recent large
population cohort study that included 308,974 births and 6163 births resulting from ART, the rate
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of birth defects in cIVF was similar to that in the general population, whereas the use of ICSI was
associated with increased risk of birth defects (OR 1.57; 95% CI, 1.30–1.90) even after controlling for
confounders [35]. More recently, there have been suggestions of an association between ICSI and an
increase of congenital heart diseases [36], intellectual disability [37], autism [37,38] and higher rates
of admission to a neonatal intensive care unit [39]. Although these trends are not confirmed in other
studies [40] and meta-analyses [41,42], the safety issue of ICSI remains a matter of current debate.
5. Conclusions
The results of this study suggest that ICSI is not associated with increased likelihood of a live
birth for unexplained, non-male factor infertility, in women aged 40 years or more. This finding is in
line with the opinion of the Practice Committee of the ASRM that ‘there are no data to support the
routine use of ICSI for non-male factor infertility [43].
Given the retrospective nature of the present and previous investigations, there is an urgent need
for randomized prospective studies, in order to show whether ICSI has any advantage over cIVF, in
particular in older women, or even whether the indiscriminate use of ICSI for non-male infertility
could be detrimental.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/10/1694/s1,
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